PURPOSE: To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma. METHODS: Of 95 children with refractory neuroblastoma treated with 131I-MIBG at UCSF, 3 have been identified with secondary myelodysplasia/leukemia. The case records and bone marrow results were reviewed, along with a review of the literature. RESULTS: Three patients developed secondary myelodysplasia/leukemia, at 7, 11, and 12 months following 131I-MIBG therapy. Cytogenetic abnormalities included -7q/-5, -7/+2q37, -11 and +12. Three additional cases were found in literature review of 509 reported patients treated with 131I-MIBG for neuroblastoma. CONCLUSIONS: Therapy with 131I-MIBG may contribute to the risk of secondary leukemia in patients who have received intensive chemotherapy, thought the risk of this complication is far lower than the risk of disease progression. Further monitoring for this complication is indicated.
PURPOSE: To describe three patients with secondary leukemia after treatment with 131I-metaiodobenzylguanidine (MIBG) for neuroblastoma. METHODS: Of 95 children with refractory neuroblastoma treated with 131I-MIBG at UCSF, 3 have been identified with secondary myelodysplasia/leukemia. The case records and bone marrow results were reviewed, along with a review of the literature. RESULTS: Three patients developed secondary myelodysplasia/leukemia, at 7, 11, and 12 months following 131I-MIBG therapy. Cytogenetic abnormalities included -7q/-5, -7/+2q37, -11 and +12. Three additional cases were found in literature review of 509 reported patients treated with 131I-MIBG for neuroblastoma. CONCLUSIONS: Therapy with 131I-MIBG may contribute to the risk of secondary leukemia in patients who have received intensive chemotherapy, thought the risk of this complication is far lower than the risk of disease progression. Further monitoring for this complication is indicated.
Authors: Lucia Martiniova; Shiromi M Perera; Frederieke M Brouwers; Salvatore Alesci; Mones Abu-Asab; Amanda F Marvelle; Dale O Kiesewetter; David Thomasson; John C Morris; Richard Kvetnansky; Arthur S Tischler; James C Reynolds; Antonio Tito Fojo; Karel Pacak Journal: Endocr Relat Cancer Date: 2011-01-13 Impact factor: 5.678
Authors: Alekist Quach; Lingyun Ji; Vikash Mishra; Aimee Sznewajs; Janet Veatch; John Huberty; Benjamin Franc; Richard Sposto; Susan Groshen; Denice Wei; Paul Fitzgerald; John M Maris; Gregory Yanik; Randall A Hawkins; Judith G Villablanca; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2010-09-09 Impact factor: 3.167
Authors: Alexei L Polishchuk; Steven G Dubois; Daphne Haas-Kogan; Randall Hawkins; Katherine K Matthay Journal: Cancer Date: 2011-03-08 Impact factor: 6.860
Authors: Kelly E Huibregtse; Kieuhoa T Vo; Steven G DuBois; Stephanie Fetzko; John Neuhaus; Vandana Batra; John M Maris; Brian Weiss; Araz Marachelian; Greg A Yanik; Katherine K Matthay Journal: Eur J Cancer Date: 2016-08-27 Impact factor: 9.162
Authors: Sara Gonias; Robert Goldsby; Katherine K Matthay; Randall Hawkins; David Price; John Huberty; Lloyd Damon; Charles Linker; Aimee Sznewajs; Steve Shiboski; Paul Fitzgerald Journal: J Clin Oncol Date: 2009-07-27 Impact factor: 44.544